| Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. | |
| | |
MedLine Citation:
|
PMID: 12356379 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effects of atorvastatin at 20, 40, and 80 mg/day on plasma lipoprotein subclasses were examined in a randomized, placebo-controlled fashion over 24 weeks in 103 patients in the fasting state who had coronary heart disease (CHD) with low-density lipoprotein (LDL) cholesterol levels >130 mg/dl. The effects of placebo and atorvastatin 40 mg/day were examined in 88 subjects with CHD in the fasting state and 4 hours after a meal rich in saturated fat and cholesterol. These findings were compared with results in 88 age- and gender-matched control subjects. Treatment at the 20, 40, and 80 mg/day dose levels resulted in LDL cholesterol reductions of 38%, 46%, and 52% (all p <0.0001), triglyceride reductions of 22%, 26%, and 30% (all p <0.0001), and high-density lipoprotein (HDL) cholesterol increases of 6%, 5%, and 3%, respectively (all p <0.05 at the 20- and 40-mg doses). The lowest total cholesterol/HDL cholesterol ratio was observed with the 80 mg/day dose of atorvastatin (p <0.0001 vs placebo). Remnant-like particle (RLP) cholesterol decreased 33%, 34%, and 32%, respectively (all p <0.0001). Lipoprotein(a) [Lp(a)] cholesterol decreased 9%, 16%, and 21% (all p <0.0001), although Lp(a) mass increased 9%, 8%, and 10%, respectively (all p <0.01). In the fed state, atorvastatin 40 mg/day normalized direct LDL cholesterol (29% below controls), triglycerides (8% above controls), and RLP cholesterol (10% below controls), with similar reductions in the fasting state. At this same dose level, atorvastatin treatment resulted in 39%, 35%, and 59% decreases in fasting triglyceride in large, medium, and small very LDLs, as well as 45%, 33%, and 47% reductions in cholesterol in large, medium, and small LDL, respectively, as assessed by nuclear magnetic resonance (all significant, p <0.05), normalizing these particles versus controls (77 cases vs 77 controls). Moreover, cholesterol in large HDL was increased 37% (p <0.001) by this treatment. Our data indicate that atorvastatin treatment normalizes levels of all classes of triglyceride-rich lipoproteins and LDL in both the fasting and fed states in patients with CHD compared with control subjects. |
| | |
Authors:
|
Ernst J Schaefer; Judith R McNamara; Timothy Tayler; Jennifer A Daly; Joi A Gleason; Leo J Seman; Andrea Ferrari; Joel J Rubenstein |
Related Documents
:
|
1106289 - Management of type iv hyperlipoproteinemia. evaluation of practical clinical approaches. 9189839 - Male and female cord blood lipoprotein profile differences throughout the term-period. 16549459 - High cholesterol intake modifies chylomicron metabolism in normolipidemic young men. 6573839 - Lipid fractions in primary hyperparathyroidism before and after surgical cure. 14618939 - Deae-dextran in the treatment of primary hypercholesterolemia and/or hypercholesterolem... 18937609 - Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic r... 20468939 - The unhappy fat woman. 16428109 - Carry-over effects of dietary yeast rna as a source of nucleotides on lymphoid organs a... 10245409 - The energy outlook: combining the options. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of cardiology Volume: 90 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2002 Oct |
Date Detail:
|
Created Date: 2002-10-01 Completed Date: 2002-10-22 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 689-96 Citation Subset: AIM; IM |
Affiliation:
|
Atherosclerosis Research Laboratory, Lipid and Heart Disease Prevention Clinic, Department of Medicine, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA. eschaefer@hnrc.tufts.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
administration & dosage,
pharmacology*,
therapeutic use Cholesterol / blood Cholesterol, HDL / blood, drug effects Cholesterol, LDL / blood, drug effects Coronary Disease / blood, prevention & control* Dietary Fats / metabolism* Dose-Response Relationship, Drug Fasting / blood* Female Heptanoic Acids / administration & dosage, pharmacology*, therapeutic use Humans Lipoprotein(a) / blood, drug effects Lipoproteins / blood, classification, drug effects* Male Middle Aged Postprandial Period* Pyrroles / administration & dosage, pharmacology*, therapeutic use Treatment Outcome Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Dietary Fats; 0/Heptanoic Acids; 0/Lipoprotein(a); 0/Lipoproteins; 0/Pyrroles; 0/Triglycerides; 110862-48-1/atorvastatin; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: [Immediate post-operative period in patients undergoing total thyroidectomy in the ICU].
Next Document: Risk stratification of obesity as a coronary risk factor.